GPS Wealth Strategies Group LLC Reduces Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

GPS Wealth Strategies Group LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,172 shares of the biopharmaceutical company’s stock after selling 367 shares during the quarter. GPS Wealth Strategies Group LLC’s holdings in Gilead Sciences were worth $478,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Avior Wealth Management LLC raised its stake in shares of Gilead Sciences by 1.2% during the 3rd quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after buying an additional 108 shares during the last quarter. Southland Equity Partners LLC raised its position in Gilead Sciences by 3.6% during the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 110 shares in the last quarter. Concord Asset Management LLC VA lifted its holdings in Gilead Sciences by 3.8% in the third quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 111 shares during the period. Berkshire Bank boosted its position in Gilead Sciences by 3.4% in the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 111 shares in the last quarter. Finally, TFB Advisors LLC grew its stake in shares of Gilead Sciences by 1.2% during the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock worth $788,000 after purchasing an additional 116 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.3 %

Shares of NASDAQ:GILD opened at $97.20 on Monday. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The business has a fifty day moving average of $92.42 and a two-hundred day moving average of $85.87. The stock has a market cap of $121.14 billion, a P/E ratio of 1,080.00, a PEG ratio of 1.34 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.29 earnings per share. On average, research analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Insider Activity

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now directly owns 8,920 shares in the company, valued at $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 456,234 shares of company stock valued at $42,130,461. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

GILD has been the subject of several analyst reports. Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $74.00 to $96.00 in a research note on Monday, October 21st. BMO Capital Markets increased their target price on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Citigroup began coverage on Gilead Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $125.00 price target for the company. Piper Sandler increased their price target on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Finally, Oppenheimer upped their target price on Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $98.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.